Antibodies in Clinic / Clinical Trials

In July 2025, the FDA granted accelerated approval to linvoseltamab, a BCMA × CD3 T-cell engaging bispecific antibody, for the treatment of ...

Bispecific...

Antibody engineering has revolutionized the development of therapeutic antibodies by introducing mutations that modulate various aspects of antibody function. This overview provides a concise summary of key mutation strategies in antibody engineering, including their benefits and challenges.

 ...

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a crucial mechanism in the immune response and a primary mode of action for many therapeutic antibodies. Enhancing ADCC through strategic mutations in the antibody structure has become a focal point in antibody engineering...

The neonatal Fc receptor (FcRn) has long been recognized for its role in regulating the half-life of IgG and albumin. However, recent research has uncovered its potential as a versatile drug delivery system. This blog post will explore the multifaceted roles of FcRn and its emerging applications in drug...